Personalis Q1 revenue falls but beats analyst estimates

Personalis

07/05/2026 21:26

Overview

US precision oncology genomics firm's Q1 revenue fell yr/yr but beat analyst expectations

Clinical test volumes surged 258% yr/yr, driven by new Medicare lung cancer coverage

Company reaffirmed full-year guidance and strategic focus on MRD offering

Outlook

Personalis sees 2026 revenue of $78 mln to $80 mln

Company expects 2026 clinical test volume of 43,000 to 45,000 tests

Personalis projects 2026 gross margin of 15% to 20%

Result Drivers

CLINICAL VOLUME SURGE - Q1 clinical test volumes rose 258% yr/yr, attributed to new Medicare coverage for lung cancer surveillance and expansion of MRD offering

SHIFT FROM NON-CORE REVENUE - Overall revenue decline reflects planned reduction in non-core revenue as company focuses on strategic MRD offering

NEW PRODUCT FEATURES AND DATA - Launch of Real-Time Variant Tracker and positive data from clinical studies and conferences supported core business growth

Company press release: ID:nBw8bKkdqa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$15.47 mln
$14.48 mln (6 Analysts)
Q1 Net Income
-$30.03 mln
Q1 Basic EPS
-$0.29
Q1 Income From Operations
-$32.16 mln
Q1 Pretax Profit
-$30.02 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Personalis Inc is $11.00, about 81.2% above its May 6 closing price of $6.07

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)